Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.St Jude Medical, a US-based medical technology company, has received regulatory approval from the Japanese Ministry of Health, Labour and Welfare, in addition to reimbursement approval, of its Atlas II implantable cardioverter defibrillator, a device used to treat patients with potentially lethal abnormal heart rhythms.
Subscribe to our email newsletter
According to the company, the Atlas II implantable cardioverter defibrillator (ICD) is a device that significantly enhances telemetry speed for faster communications – up to five times faster than predecessor devices – which results in quicker, more convenient follow-up visits for patients and physicians.
William Phillips, president of St Jude Medical Japan, said: “The Atlas II devices offer important clinical benefits due to their high-energy capability, advanced diagnostics and increased telemetry speed. Customized options give physicians more control and help simplify patient management through better detection, diagnosis and delivery of tailored therapy.”